Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor‐kappa B ligand, and high‐sensitivity C‐reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate

References

• Walsh N. C., Crotti T. N., Goldring S. R., Gravallese E. M. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005; 208: 228–51
   PubMed Web of Science ®Google Scholar
• Denhardt D. T., Noda M., O'Regan A. W., Pavlin D., Berman J. S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107: 1055–61
   PubMed Web of Science ®Google Scholar
• O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003; 14: 479–88
   PubMed Web of Science ®Google Scholar
• Petrow P. K., Hummel K. M., Schedel J., Franz J. K., Klein C. L., Muller‐Ladner U., et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000; 43: 1597–605
   PubMedGoogle Scholar
• Xu G., Nie H., Li N., Zheng W., Zhang D., Feng G., et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 2005; 115: 1060–7
   PubMed Web of Science ®Google Scholar
• Xu G., Sun W., He D., Wang L., Zheng W., Nie H., et al. Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 2005; 32: 410–16
   PubMedGoogle Scholar
• Ohshima S., Yamaguchi N., Nishioka K., Mima T., Ishii T., Umeshita‐Sasai M., et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002; 29: 2061–7
   PubMed Web of Science ®Google Scholar
• Ziolkowska M., Kurowska M., Radzikowska A., Luszczykiewicz G., Wiland P., Dziewczopolski W., et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti‐tumor necrosis factor alpha treatment. Arthritis Rheum 2002; 46: 1744–53
   PubMed Web of Science ®Google Scholar
• Skogh T., Gustafsson D., Kjellberg M., Husberg M. Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rate. Ann Rheum Dis 2003; 62: 681–2
   PubMed Web of Science ®Google Scholar
• van Riel P. L., Taggart A. J., Sany J., Gaubitz M., Nab H. W., Pedersen R., et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65: 1478–83
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R. F., Ernestam S., Harju A., Bratt J., Klareskog L., et al. Etanercept versus etanercept plus methotrexate: a registry‐based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003; 5: R347–51
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9
   PubMed Web of Science ®Google Scholar
• Klareskog L., van der H. D., de Jager J. P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double‐blind randomised controlled trial. Lancet 2004; 363: 675–81
   PubMed Web of Science ®Google Scholar
• Genovese M. C., Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443–50
   PubMed Web of Science ®Google Scholar
• Dohn U. M., Skjodt H., Hetland M. L., Vestergaard A., Moller J. M., Knudsen L. S., et al. No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation. Clin Rheumatol 2007; 26: 1857–861
   PubMed Web of Science ®Google Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Fransen J., van Riel P. L. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23: S93–9
   PubMed Web of Science ®Google Scholar
• Sennels H. P., Jacobsen S., Jensen T., Hansen M. S., Ostergaard M., Nielsen H. J., et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high‐sensitivity C‐reactive protein. Scand J Clin Lab Invest 2007; 67: 821–35
   PubMed Web of Science ®Google Scholar
• Ashkar S., Weber G. F., Panoutsakopoulou V., Sanchirico M. E., Jansson M., Zawaideh S., et al. Eta‐1 (osteopontin): an early component of type‐1 (cell‐mediated) immunity. Science 2000; 287: 860–4
   PubMed Web of Science ®Google Scholar
• Yumoto K., Ishijima M., Rittling S. R., Tsuji K., Tsuchiya Y., Kon S., et al. Osteopontin deficiency protects joints against destruction in anti‐type II collagen antibody‐induced arthritis in mice. Proc Natl Acad Sci USA 2002; 99: 4556–61
   PubMed Web of Science ®Google Scholar
• Ishii T., Ohshima S., Ishida T., Mima T., Tabunoki Y., Kobayashi H., et al. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. Biochem Biophys Res Commun 2004; 316: 809–15
   PubMedGoogle Scholar
• Vis M., Havaardsholm E. A., Haugeberg G., Uhlig T., Voskuyl A. E., van de Stadt R. J., et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1495–9
   PubMed Web of Science ®Google Scholar
• Catrina A. I., Klint E. A., Ernestam S., Catrina S. B., Makrygiannakis D., Botusan I. R., et al. Anti‐tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006; 54: 76–81
   PubMedGoogle Scholar
• Feuerherm A. J., Borset M., Seidel C., Sundan A., Leistad L., Ostensen M., et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 229–34
   PubMed Web of Science ®Google Scholar
• Haynes D. R., Barg E., Crotti T. N., Holding C., Weedon H., Atkins G. J., et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology (Oxford) 2003; 42: 123–34
   PubMed Web of Science ®Google Scholar
• Vanderborght A., Linsen L., Thewissen M., Geusens P., Raus J., Stinissen P. Osteoprotegerin and receptor activator of nuclear factor‐kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 2004; 31: 1483–90
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Alvaro I., Ortiz A. M., Tomero E. G., Balsa A., Orte J., Laffon A., et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1675–8
   PubMed Web of Science ®Google Scholar
• Genta M. S., Kardes H., Gabay C. Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti‐TNF‐alpha in the community. Joint Bone Spine 2006; 73: 51–6
   PubMedGoogle Scholar
• Morita Y., Fukazawa T., Hirashima M., Kaga K., Kusaoi M., Morita T., et al. The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol 2006; 35: 268–72
   PubMed Web of Science ®Google Scholar